Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
OncoMedX – Oncology Pharmaceutical Consulting from Lennik, company number BE0738436452, closed financial year 2025 with a result of € -96 after tax. For that financial year OncoMedX – Oncology Pharmaceutical Consulting recorded a gross margin of € -66 and equity of € -23,172. Compared with financial year 2024, the result moved from € -30 to € -96. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
€ -23,172
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -96
▼ 219 % more loss than in 2024
Profit after tax over the fiscal year.
€ 6,701
▼ 6% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -28,172.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 587 | - | - | € -66 | |
| Profit after taxes | € -8,720 | € -122 | € -30 | € -96 | ▼ € 66 |
| Equity | € -22,924 | € -23,046 | € -23,076 | € -23,172 | |
| Total debts | € 48,373 | € 29,894 | € 30,222 | € 29,873 | ▼ 1% |
| Cash | € 4,266 | € 4,532 | € 7,146 | € 6,701 | ▼ 6% |
| Retained profit | € -27,924 | € -28,046 | € -28,076 | € -28,172 | |
| Balance sheet total | € 25,449 | € 6,848 | € 7,146 | € 6,701 | ▼ 6% |
Key figures of OncoMedX – Oncology Pharmaceutical Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to OncoMedX – Oncology Pharmaceutical Consulting?
What happened at OncoMedX – Oncology Pharmaceutical Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 96. filed late Source: NBB ↗
- New establishment in Lennik. KBO
- LUDWIG VAN DEN HOVE became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 8,720 loss in 2022 to € 96 loss in 2025.
Paid € 47 in corporate taxes since 2022.
Management
Behind OncoMedX – Oncology Pharmaceutical Consulting is LUDWIG VAN DEN HOVE.
Directors
According to the 2025 annual accounts
LUDWIG VAN DEN HOVE
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Saffelbergstraat 19B
1750 Lennik
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.436.452
- VAT number
- BE 0738.436.452
- Registered office
- Saffelbergstraat 19B, 1750 Lennik
- Names & denominations
- OncoMedX – Oncology Pharmaceutical Consulting · OncoMedX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2019
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie